Determinants of Response to Sequential Pembrolizumab with Trastuzumab Plus Platinum/5FU in HER2-positive Gastric Cancer: A Phase II Chemoimmunotherapy Trial
Clin. Cancer Res., February 17 2025 | https://doi.org/10.1158/1078-0432.CCR-24-3528
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD1 therapy
Ann. Oncol., Available online 25 October 2021 | https://doi.org/10.1016/j.annonc.2021.10.009